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Abstract
Introduction Gallstones are the most common cause of acute
pancreatitis worldwide. Patients with severe acute biliary
pancreatitis (SABP) constitute a subgroup of severe acute
pancreatitis (SAP) patients in whom systemic inflammation may
be triggered and perpetuated by different mechanisms. The aim
of this prospective investigation was to examine the adrenal
response to corticotropin and the relationship between adrenal
function and outcome in patients with SABP.
Methods Thirty-two patients with SABP were enrolled in this
study. A short corticotropin (250 g) stimulation test (SST) was
performed within the first 24 hours of admission to the ICU.
Critical illness related corticosteroid insufficiency (CIRCI) was
defined as follows: baseline value less than 10 g/dL, or cortisol
response less than 9 g/dL.
Results CIRCI occurred in 34.4% of patients. The patients with
CIRCI were more severely ill as evidenced by higher APACHE II
and SOFA scores and numbers of organ system dysfunction on
the day of SST. The in-hospital mortality for the entire group was
21.9%. The CIRCI group had a higher hospital mortality rate
compared to those with normal adrenal function (45.5% vs.
9.5%, P = 0.032). The hospital survivors had a higher cortisol
response to corticotropin (17.4 (8.3–27.1) vs. 7.2 (1.7–12) g/
dL, P = 0.019). The cortisol response to corticotropin inversely
correlated with SOFA score and the number of organ
dysfunction on the day of SST. The rates of pancreatic necrosis
and bacteremia were significantly higher in the CIRCI group
(100% vs 42.9%, P = 0.002; 81.8% vs 23.8%, P = 0.003,
respectively).
Conclusions CIRCI is common in patients with SABP. It is
associated with bacteremia, multiple organ dysfunction and
increased mortality.
Introduction
Acute pancreatitis represents an acute inflammatory disorder
with variable severity ranging from a mild, self-limited disease
to a severe inflammatory cascade associated with multiple-
organ dysfunction. Most mortality from acute pancreatitis is a
consequence of multiple-organ dysfunction [1,2]. The precise
mechanisms by which various etiological factors induce an
acute attack are still unclear, but once the disease process is
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started, common inflammatory pathways are invoked. Initially,
inflammatory reaction takes place within the pancreas, which
can lead to systemic inflammatory response syndrome (SIRS);
it is this systemic response that eventually contributes to mul-
tiple-organ dysfunction [3]. In fact, there is a bimodal distribu-
tion of mortality from acute pancreatitis. Approximately one-
half of all mortality cases occurs early with a severe attack that
results from the development of SIRS and subsequent multi-
ple-organ dysfunction. Patients with severe acute pancreatitis
(SAP) who die later in the clinical course often succumb to
septic complications [1,2]. Despite improvements in critical
care, early mortality remains a major contributory factor to
overall mortality from acute pancreatitis, and continues to rep-
resent a clinical challenge [4,5]. It has been shown that early
multiple-organ dysfunction syndrome (MODS) is not only
responsible for the early mortality in patients with SAP, but it
also identifies those patients most at risk of death from later
septic complications [1]. The systemic effects of SAP share
many similarities with those of other critical illness such as
severe sepsis, liver failure, burns, and trauma [6-8]. They are
all characterized by systemic inflammation, which potentially
results in single-organ or multiple-organ dysfunction.
Critical illness is accompanied by the activation of the hypoth-
alamic-pituitary-adrenal axis, which is highlighted by increased
serum corticotropin and cortisol levels [9,10]. The activation of
the hypothalamic-pituitary-adrenal axis is a crucial component
of the host's adaptation to severe stress. Cortisol is essential
for the normal function of the immune system and various cel-
lular functions. Recently, the concept of critical illness-related
corticosteroid insufficiency (CIRCI) has been put forward to
describe a subnormal adrenal response to adrenocorticotro-
pin in severe illness, in which the cortisol levels, although high
in terms of absolute value, are inadequate to control the inflam-
matory situation [7-11]. The short corticotropin stimulation test
(SST) is most commonly used to evaluate the appropriateness
of the adrenal response in this setting [9,11]. Indeed, in
patients with septic shock, a decreased response to the SST,
namely an absolute increment of the serum cortisol level less
than 9 g/dL, is associated with an increased mortality [12-
14]. Recently, accumulating evidence has suggested that
CIRCI may also be involved in the pathogenesis of systemic
inflammation in SAP [15-18].
Gallstones are recognized as the leading cause of acute pan-
creatitis worldwide [19]. In contrast to other etiological enti-
ties, the natural history of acute biliary pancreatitis is
characterized by higher rates of bacteremia, cholangitis, pan-
creatic abscess, and infected necrosis; on the other hand, it is
also marked by lower incidences of pseudocysts, splenic vein
thrombosis, and chronic pancreatitis [19]. Recently, bactere-
mia has been identified as an independent factor associated
with mortality in patients with acute pancreatitis [20]. In fact,
bacteremia has also been shown to be an independent factor
to predict CIRCI in patients with severe sepsis and septic
shock [8,21]. Taken together, severe acute biliary pancreatitis
(SABP) may constitute a subset in which the prevalence,
mechanisms, and impacts of CIRCI may be different from
those in other etiological entities. Indeed, patients with SABP
may represent a subgroup of SAP patients in whom systemic
inflammation is triggered and perpetuated by different mecha-
nisms. Despite the growing interest in the association
between adrenal dysfunction and SAP [22], adrenal respon-
siveness in SABP has, to the authors' knowledge, never been
investigated explicitly. The aim of this investigation is to exam-
ine the adrenal response to corticotropin and the relation
between adrenal function and outcome in patients with SABP.
Materials and methods
Patient information, data collection, and definitions
This study was conducted with approval from the institutional
review board of Chang Gung Memorial Hospital, Taiwan, and
in accordance with the Declaration of Helsinki of the World
Medical Association. Written informed consent was obtained
from the patients' relatives and next of kin This study was per-
formed in the intensive care unit (ICU) of two university-affili-
ated hospitals between November 2004 and May 2006. The
study enrolled 32 consecutive patients with SABP requiring
intensive monitoring and/or treatment. The pancreatitis was
considered to be of a biliary origin if gallstones were identified
on ultrasonography or computed tomography (CT) scans and
in the absence of other known etiological factors. Severe pan-
creatitis was defined according to the Atlanta criteria [23].
Patients were enrolled when one or more of the following were
present: a Ranson score of three or higher, an Acute Physiol-
ogy and Chronic Health Evaluation (APACHE) II score of eight
or higher, or failure of one or more organs. Organ failure was
defined as systolic blood pressure less than 90 mmHg, partial
pressure of arterial oxygen (PaO2) less than 60 mmHg, or
serum creatinine level greater than 2 mg/dL. Patients with a
history of prior acute pancreatitis or corticosteroid treatment,
and those who had received the steroidogenesis-inhibiting
agent etomidate were excluded from this study. All ICU admis-
sions were followed until discharge from the hospital or hospi-
tal mortality.
Vasopressor dependency was defined by a need for vasoac-
tive substance(s) to maintain a systolic blood pressure greater
than 90 mmHg despite volume expansion. Bacteremia was
defined as the presence of viable bacteria in the blood [6], as
evidenced by a positive blood culture up to three days before
SST.
Organ function on the day of SST was evaluated using
sequential organ failure assessment (SOFA) score [24].
Organ dysfunction was defined as previously described
[18,24] and based on a score of two or more for any organ
system in the SOFA score [24]. The hepatic scores were dis-
regarded to preclude the confounding effects of obstructive
jaundice induced by biliary stones. The cut-offs forAvailable online http://ccforum.com/content/13/4/R123
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dysfunctional organ systems were as follows: cardiovascular
system, vasopressor dependency, namely dopamine at doses
higher than 2 g/kg/min or norepinephrine dobutamine at any
dose; respiratory system, PaO2/fraction of inspired oxygen
(FiO2) ratio less than 300; kidneys, serum creatinine level
higher than 2 mg/dL; central nervous system, Glasgow coma
score lower than 13; coagulation, platelet count lower than
100 × 109/L.
Abdominal ultrasonography was performed for each case at
presentation. Enhanced CT was performed when the disease
was classified as severe. A CT-guided aspiration was per-
formed and bacterial cultures were obtained when infected
necrosis or abscess was suspected.
Laboratory investigations
Blood cultures and appropriate cultures from the infection
focus were obtained [25]. Prospectively collected information
also included hematological and biochemical data, which are
necessary to calculate various prognostic scores.
An SST was performed within the first 24 hours of admission
to the ICU, with a median of three days (interquartile range
(IQR) two to four) after the start of symptoms and a median of
two days (IQR one to three) after admission to hospital. Syn-
thetic adrenocorticotropic hormone 250 g (Synacthen,
Novartis Pharma AG, Basle, Switzerland) was given intrave-
nously. Blood samples were obtained immediately before, and
30 and 60 minutes after injection. Cortisol levels were meas-
ured by a competitive immunoassay using direct chemilumi-
nescent technology (Bayer Corporation, East Walpole, MA,
USA). The peak cortisol level was defined as the highest cor-
tisol level obtained following synacthen administration,
whether at 30 or 60 minutes. The cortisol response was
defined as the difference between the baseline and peak cor-
tisol levels. The criteria for CIRCI were described previously
Table 1
Demographic data and clinical characteristics
All Patients
(n = 32)
Hospital Survivors
(n = 25)
Hospital Non-survivors
(n = 7)
P value
Age (years) 68 (55 to 79) 68 (55 to 81) 75 (55 to 80) NS (0.293)
Gender (M/F) 12/20 9/16 3/4 NS (1.000)
BUN 15.5 (10.5 to 36.5) 14 (8.5 to 20.5) 40 (17 to 80) < 0.001
Serum creatinine (mg/dl) 1.1 (0.6 to 1.9) 0.9 (0.6 to 1.4) 3.7 (2 to 4.2) < 0.001
Bilirubin (mg/dl) 1.6 (0.8 to 3.2) 1.5 (0.7 to 2.6) 5.1 (1.2 to 11.5) 0.006
Albumin (g/l) 2.8 (2.4 to 3) 2.8 (2.4 to 3.1) 2.6 (2.3 to 2.8) NS (0.090)
INR 1.2 (1.2 to 1.4) 1.2 (1.2 to 1.4) 1.3 (1.2 to 1.5) NS (0.399)
MAP (mmHg) 79 (60 to 90) 81 (68 to 92) 60 (57 to 75) 0.041
SOFA score on the day of SST 5 (3 to 9) 4 (2.3 to 6.8) 12 (10 to 16) 0.001
APACHE II score on the day of SST 15 (10 to 20) 14 (9.5 to 18) 20 (15 to 36) 0.006
Ranson score 5 (3 to 6) 4 (3 to 5.5) 8 (5 to 9) 0.005
CIRCI (%) 11 (34.4) 6 (24) 5 (71.4) 0.032
Baseline cortisol (g/dL) 21.6 (17.1 to 36) 20.7 (16.4 to 31.6) 28 (19.1 to 39.1) NS (0.368)
Peak cortisol (g/dL) 39.2 (32.1 to 46.8) 39.2 (32.5 to 47.1) 39.1 (29.7 to 46) NS (0.316)
Cortisol increment (g/dL) 14.5 (3.3 to 25.3) 17.4 (8.3 to 27.1) 7.2 (1.7 to 12) 0.019
Bacteremia (%) 14 (43.8) 10 (40) 4 (57.1) NS (0.669)
Number of organ dysfunction on the day of SST 2 (1 to 3) 1 (1 to 2) 4 (3 to 5) < 0.001
Respiratory dysfunction (%) 23 (71.9) 16 (69.6) 7 (100) NS (0.149)
Coagulation dysfunction (%) 7 (21.9) 3 (12) 4 (57.1) 0.026
Cardiovascular dysfunction (%) 10 (31.3) 5 (20) 5 (71.4) 0.019
CNS dysfunction (%) 14 (43.8) 8 (32) 6 (85.7) 0.0287
Renal dysfunction (%) 12 (37.5) 5 (20) 7 (100) < 0.001
APACHE = Acute Physiology and Chronic Health Evaluation; BUN = blood urea nitrogen; CIRCI = critical illness related corticosteroid 
insufficiency; CNS = central nervous system; F = female; INR = international normalized ratio; M = male; MAP = mean arterial pressure; NS = not 
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[11] and are defined as follows: baseline value less than 10
g/dL, or cortisol response less than 9 g/dL.
Statistical analysis
Results are expressed as median with IQR unless otherwise
stated. Continuous variables were compared using the Mann-
Whitney U test. Categorical data were tested using the chi-
squared test. The correlation between the results of the SST
and various prognostic scores was analyzed with linear regres-
sion using the Pearson method. All statistical tests were two-
tailed, and the significance level was set at P  0.05. Data
were analyzed using SPSS 10.0 for Windows (SPSS Inc.,
Chicago, IL, USA).
Results
Subjects' characteristics
Thirty-two critically ill patients with SABP were enrolled in this
investigation. The median patient age was 68 years. There
were 12 men (37.5%) and 20 women (62.5%). Overall, the in-
hospital mortality for the entire group was 21.9%.
Table 1 lists the patients' demographic data, clinical character-
istics, and results of the SST for both survivors and non-survi-
vors. The median number of organ dysfunctions on the day of
SST was significantly higher among non-survivors (Table 1).
Short corticotropin stimulation test
As shown in Table 1, the response to corticotropin was signif-
icantly higher in those who survived, while the baseline and
peak cortisol levels were not different between survivors and
non-survivors. According to the aforementioned criteria, 11
(34.37%) patients had CIRCI. All 11 patients had a cortisol
response less than 9 g/dL. None of these 11 patients had a
baseline level less than 10 g/dL. The clinical characteristics
and outcomes of patient subgroups stratified by adrenal func-
tions are listed in Table 2. The ICU and hospital mortality rates
of the patients with CIRCI were significantly higher than for
Table 2
Demographic data and clinical characteristics grouped according to adrenal function
All patients
(n = 32)
Adrenal insufficiency
(n = 11)
Normal adrenal function
(n = 21)
P value
Age (years) 68 (55 to 80) 73 (58 to 80) 68 (55 to 81) NS (0.685)
Gender (M/F) 12/20 4/7 8/13 NS (0.923)
ICU mortality (%) 6 (18.8) 5 (45.5) 1 (4.8) 0.011
Hospital mortality (%) 7 (21.9) 5 (45.5) 2 (9.5) 0.032
BUN (mg/dl) 15.5 (10.5 to 36.5) 23 (12 to 45) 15 (8.5 to 23.5) NS (0.293)
Serum creatinine (mg/dl) 1.1 (0.6 to 1.9) 2.5 (1.1 to 3.7) 0.9 (0.6 to 1.3) 0.003
Bilirubin (mg/dl) 1.6 (0.8 to 3.2) 5.1 (1.9 to 9.6) 1.4 (0.7 to 2.0) 0.004
Albumin (g/l) 2.8 (2.4 to 3) 2.8 (2.4 to 2.8) 2.8 (2.2 to 3.1) NS (0.839)
INR 1.2 (1.2 to 1.4) 1.3 (1.2 to 1.5) 1.2 (1.2 to 1.3) NS (0.568)
MAP (mmHg) 79 (60 to 90) 58 (57 to 60) 84 (79 to 93) < 0.001
SOFA score on the day of SST 5 (3 to 9) 11 (7 to 15) 4 (2 to 6) < 0.001
APACHE II score on the day of SST 15 (10 to 20) 20 (10 to 27) 15 (11 to 18) 0.018
Ranson score 5 (3 to 6) 7 (5 to 9) 4 (3 to 5) < 0.001.
Necrosis (%) 20 (62.5) 11 (100) 9 (42.9) 0.002
Bacteremia (%) 14 (43.8) 9 (81.8) 5 (23.8) 0.003
Number of organ dysfunction on the day of SST 2 (1 to 3) 4 (2.5 to 5) 1 (1 to 2) < 0.001
Respiratory dysfunction (%) 23 (71.9) 9 (81.8) 14 (66.7) NS (0.441)
Coagulation dysfunction (%) 7 (21.9) 7 (63.6) 0 (0) < 0.001
CV dysfunction (%) 10 (31.3) 9 (81.8) 1 (4.8) < 0.001
CNS dysfunction (%) 14 (43.8) 6 (54.5) 8 (38.1) NS (0.465)
Renal dysfunction (%) 12 (37.5) 7 (63.6) 5 (23.8) 0.027
APACHE = Acute Physiology and Chronic Health Evaluation; BUN = blood urea nitrogen; CIRCI = critical illness related corticosteroid 
insufficiency; CNS = central nervous system; CV = cardiovascular; F = female; ICU = intensive care unit; INR = international normalized ratio; M 
= male; MAP = mean arterial pressure; NS = not significant; SOFA = sequential organ failure assessment; SST = short corticotropin stimulation 
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those with normal adrenal function (45.5% vs 4.8%, and
45.5% vs 9.5%, respectively, P = 0.011 and 0.032, respec-
tively). The incidence of CIRCI increased progressively and
significantly with the number of organ system dysfunctions
(chi-squared for trend, P = 0.001, Figure 1). The incremental
response to corticotropin was negatively correlated with the
SOFA score (R = -0.681; P < 0.001) and the number of organ
system dysfunctions on the day of SST (R = -0.660; P <
0.001), while the baseline cortisol level was positively corre-
lated with SOFA (R = 0.363, P = 0.045). However, there was
no correlation between peak cortisol level and SOFA score on
the day of SST.
Patients with CIRCI had a more severe disease as evidenced
by higher APACHE II and SOFA scores on the day of SST
(Table 2). Additionally, the rate of pancreatic necrosis was sig-
nificantly higher in the patients with CIRCI (Table 2). The
results of SST when patients were grouped according to
organ dysfunction were shown in Figure 2. On the day of the
SST, 23 (71.8%) patients had respiratory dysfunction; 14
(43.7%) had central nervous system (CNS) dysfunction; 12
(37.5%) had renal dysfunction; 10 (31.3%) had cardiovascu-
lar dysfunction; 7 (21.9%) had coagulation dysfunction. The
incremental increase of cortisol levels was significantly lower
in patients with cardiovascular, coagulation, and renal dys-
functions, while the baseline cortisol levels were significantly
higher in those patients with renal and coagulation dysfunc-
tions (Figure 2). There was no difference in SST between
those patients with respiratory, or CNS dysfunctions and
those with satisfactory respiratory and CNS functions.
Microbiological information was available for all patients.
Patients with bacteremia on the day of SST had a higher inci-
dence of CIRCI compared with non-bacteremic patients
(64.3% vs 11.1%, P = 0.003). The incremental increase of
cortisol levels was significantly lower in patients with bactere-
mia (Figure 3).
Discussion
This study shows that impaired adrenal function, as evidenced
by the SST, is common in patients with SABP. CIRCI is asso-
ciated with bacteremia, as well as increased rates of pancre-
atic necrosis, organ dysfunction, and mortality.
The evolution of organ dysfunction in patients with SAP has
been described by Buter and colleagues [1]. Despite the
bimodal distribution of mortality from SAP, the common cause
of death is MODS [1]. Early MODS not only contributes to
mortality in the early course of SAP but also represents the
most significant non-fatal complication of SAP, causing major
morbidity, and a strain on medical expenditure [26,27]. Con-
sistent with previous investigations of patients with SAP [1,2],
respiratory dysfunction is the common organ system dysfunc-
tion in SABP. However, hospital mortality in the present study
was characterized by MODS in which respiratory dysfunction
was accompanied by dysfunction of other organ systems.
MODS occurring in the early stage of SAP share many similar-
ities with severe sepsis and septic shock. The profiles of
inflammatory mediators in SAP are similar to those in severe
sepsis, suggesting that there may be common mechanisms
behind uncontrolled inflammation and organ dysfunctions in
both conditions [28]. The pathophysiology of MODS in SAP
appears to be related to the systemic activation of various
effector cells and inflammatory mediators that can act on
remote organs [28]. Despite advances in the understanding of
the pathophysiology of MODS in SAP, the outcomes of SAP
remain unsatisfactory. In fact, attempts to ameliorate the SIRS
using platelet activating factors failed to modify the course of
MODS in SAP, suggesting that our knowledge of MODS in
SAP is incomplete [29]. Recently, CIRCI has been recognized
as an important phenomenon in the pathophysiological cas-
cade of severe sepsis and septic shock [9,11]. It has also
been shown that impaired adrenal response is associated with
MODS and poor prognosis in patients with severe sepsis
[30,31]. In our study, there was a negative correlation between
cortisol increment and the number of organ system dysfunc-
tions on the day of SST, suggesting that adrenal dysfunction
is also related to MODS and poor prognosis in the setting of
SABP. In this regard, accumulating lines of evidence indicate
that CIRCI may contribute to the amplified systemic inflamma-
tory response and modify the severity and pathological course
of acute pancreatitis [15,18,32,33]. In fact, Abe and col-
leagues have demonstrated in experimental models of acute
pancreatitis that inflammation is more severe and mortality is
increased in adrenalectomized rats, suggesting that endog-
enous glucocorticoid may play an important role in mitigating
the progress of inflammation [32]. Endogenous glucocorti-
coids may also play an important role in protecting acinar cells
by decreasing their sensitivity to apoptosis during acute pan-
Figure 1
The rate of critical illness-related corticosteroid insufficiency increased  progressively and significantly with the number of organ system  dysfunctions The rate of critical illness-related corticosteroid insufficiency increased 
progressively and significantly with the number of organ system 
dysfunctions.Critical Care    Vol 13 No 4    Peng et al.
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creatitis, thus suggesting that an inadequate glucocorticoid
response in SAP can facilitate pancreatic necrosis [33].
Consistent with the previous observation of non-selected
patients with SAP [18], the non-survivors among our patients
with SABP had significantly lower cortisol increments to
adrenocorticotropic hormone stimulation, suggesting an
impaired anti-inflammatory response in those patients who
succumbed. In the present study, all the patients with CIRCI
developed pancreatic necrosis, although the causal relation
between CIRCI and the formation of necrosis has not yet been
definitively determined.
Cardiovascular dysfunction is a frequent complication of SAP.
It also represents a risk for mortality [2]. In the present study,
we showed that cardiovascular dysfunction was associated
with CIRCI and hospital mortality in patients with SABP. Like
vascular hyporeactivity to vasopressor in sepsis, patients with
occult adrenal dysfunction have an impaired responsiveness
to norepinephrine [34]. Indeed, steroid replacement may
reverse the blunt response to vasopressor and improve the
outcomes of septic patients with adrenal dysfunction [35,36].
These immunologic and hemodynamic effects of hydrocorti-
sone in severe sepsis may result from the inhibition of
cytokines and nitric oxide [37], which also mediate systemic
inflammation and hemodynamic impairment in SAP [3,28]. In
fact, steroid administration can also reduce vasopressor
dependency in SAP with shock, as was found in a retrospec-
tive case-controlled study [16]. Considering the recent inter-
est in the anti-inflammatory treatment of SAP, a subset of
patients with SAP may benefit from glucocorticoids, owing to
their anti-inflammatory effects and benefits in SAP with CIRCI.
A prospective randomized study is needed to clarify the risks
and benefits of glucocorticoid treatment in patients with SAP.
Figure 2
Results of the SSTs Results of the SSTs. (a) Results of the short corticotropin stimulation test (SST) in patients with respiratory dysfunction compared with those with-
out respiratory dysfunction. (b) Results of the SST in patients with coagulation dysfunction compared with those without coagulation dysfunction. 
(c) Results of the SST in patients with cardiovascular (CV) dysfunction compared with those without CV dysfunction. (d) Results of the SST in 
patients with central nervous system (CNS) dysfunction compared with those without CNS dysfunction. (e) Results of the SST in patients with renal 
dysfunction compared with those without renal dysfunction. Results are expressed as median, with error bars representing the interquartile range. * 
P < 0.05; ** P < 0.01.Available online http://ccforum.com/content/13/4/R123
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We observed that bacteremia is associated with CIRCI in
patients with SABP. Patients with SAP are not an entirely
homogenous group in terms of etiological factors. It has been
shown that SABP is associated with higher rates of cholangi-
tis and bacteremia [19,38,39]. In fact, bacteremia has been
suggested to be a prognostic marker to predict infected
necrosis and poor outcome in acute pancreatitis [20]. On the
other hand, bacteremia has been shown to be an independent
factor that predicts CIRCI in patients with severe sepsis and
septic shock [8,21]. The presence of viable bacteria in the
blood may reflect a higher bacterial load in a more immuno-
compromised host. In the current investigation, the cortisol
increment was significantly lower in the bacteremic group (Fig-
ure 3), implying altered adrenal synthesis and responsiveness
in this specific subset of patients. Considering the increased
bacteremic events associated with SABP and the prognostic
significance they may carry, further investigations into the
pathophysiology of impaired adrenal function may help in
improving the treatment strategy in this clinical setting.
Conclusions
CIRCI is common among patients with SABP. CIRCI is asso-
ciated with bacteremia, MODS, and increased mortality, and it
occurs more frequently in patients with more severe disease.
Whether glucocorticoid supplements in this subset of patients
can mitigate multiple-organ dysfunction and improve out-
comes remains to be clarified.
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